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Abstract
Background: A multicenter genome-wide association scan for Crohn’s Disease (CD) has recently reported 40 CD
susceptibility loci, including 29 novel ones (19 significant and 10 putative). To gain insight into the genetic overlap between
CD and ankylosing spondylitis (AS), these markers were tested for association in AS patients.
Principal Findings: Two previously established associations, namely with the MHC and IL23R loci, were confirmed. In
addition, rs2872507, which maps to a locus associated with asthma and influences the expression of the ORMDL3 gene in
lymphoblastoid cells, showed a significant association with AS (p = 0.03). In gut biopsies of AS and CD patients, ORMDL3
expression was not significantly different from controls and no correlation was found with the rs2872507 genotype
(Spearman’s rho: 20.067). The distribution of p-values for the remaining 36 SNPs was significantly skewed towards low p-
values unless the top 5 ranked SNPs (ORMDL3, NKX2–3, PTPN2, ICOSLG and MST1) were excluded from the analysis.
Conclusions: Association analysis using risk variants for CD led to the identification of a new risk variant associated with AS
(ORMDL3), underscoring a role for ER stress in AS. In addition, two known and five potentially relevant associations were
detected, contributing to common susceptibility of CD and AS.
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Introduction
Genomewide association studies (GWAS) are revealing increasing
numbers of common risk variants for a growing list of pathologies.
Common themes emerging from GWAS include (i) the polygenic
architecture of most common diseases, including many risk variants
with individually small effects, (ii) the absence of convincing epistatic
interactions between common risk variants, and (iii) the fact that the
common variants detected to date typically account for less than
20% of the genetic risk. Association mapping greatly benefits from
meta-analyses, as pooling of medium sized cohorts considerably
increases the power to detect the mainly small genetic effects [1].
An additional noteworthy outcome of recent GWAS are the
connections that are being established between diseases initially
considered unrelated, through the identification of shared risk
variants. Examples include the association of IL23R variants with
Crohn’s disease (CD), psoriasis and ankylosing spondylitis, of
PTPN2 variants with CD and type 1 diabetes, and of ORMDL3
variants with asthma and CD [2–7].
Crohn’s disease and ankylosing spondylitis (AS) are idiopathic,
chronic inflammatory disorders of, respectively, the intestinal tract
and the spine and sacroiliac joints [8,9]. Although very distinct and
well defined entities, there is clinical and genetic evidence
supporting some degree of overlap between the pathogenesis of
the two entities. Crohn’s disease is associated in up to 30% of the
patients with articular pathology including sacroilliitis, spondylitis
and/or peripheral arthritis [10]. Prior studies also demonstrated
evidence for the presence of asymptomatic chronic intestinal
inflammation in a subgroup of patients with spondylarthritis (SpA)
associated with an increased risk for the development of CD [11].
HLA-B27 has been known for a long time to be a major risk factor
for AS [12], while the previously suspected influence of the MHC
on CD susceptibility has recently been clearly confirmed [7]. As
mentioned before, IL23R variants have been shown to be associated
with both CD and AS [2,4]. Risk variants for CD in NOD2 have also
been shown to increase the risk for chronic gut inflammation in SpA
patients [13]. Finally, animal models including HLA-B27/human
b2-microglobulin transgenic rats and TNFDARE mice, support links
between articular and gut inflammation [14,15].
Through a meta-analysis involving a total of 6,894 CD cases
and 9,316 controls of Caucasian descent, we recently identified 19
novel CD risk loci in addition to 11 previously identified ones.
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Moreover, we presented strongly suggestive evidence for at least
10 more loci, for a total of 40 CD risk loci [7]. To further examine
the potential overlap between the inherited susceptibility to CD
and AS, we genotyped a cohort of 182 AS patients for SNP
markers corresponding to 39 of these 40 CD risk loci described in
Barrett et al. and evaluated their effect on AS outcome [7]. NOD2
was not included in the analysis because we and others have shown
that none of the three CD-associated SNPs are associated with AS
[13,16].
Results
As expected, a highly significant association (p= 0.00004) was
found with rs3763313, corresponding to the well established major
effect of the MHC [12]. In addition, we observed a nominally
significant association (p = 0.04) with rs11209026, which is in
agreement with the previously described effect on AS of the IL23R
locus (Supporting Table S1) [4].
Of the remaining 37 SNPs, rs2872507 showed a significant
association with AS after Bonferroni correction for 37 new tests
(p = 0.03), this being a strong candidate for a novel AS
susceptibility locus. Because this SNP has been shown to influence
the expression of the ORMDL3 gene [7], we measured the
transcript abundance of this gene in endoscopically healthy
intestinal biopsies of patients with AS, CD and ulcerative colitis
(UC) (patient characteristics Table 1). No difference was found in
ORMDL3 mRNA expression in the colon or ileum of CD, UC and
AS patients as compared to healthy controls. In addition, no
correlation was found between the expression of this gene and the
rs2872507 genotype AA/AG/GG (Spearman’s Rho:2147 for the
total group, N= 82; 0.147 for ileal biopsies only, N= 32; 0.138 for
colonic biopsies only, N= 50).
None of the other 36 SNPs yielded significant p-values after
Bonferroni correction, which was not really a surprise given the
small size of the studied AS cohort. However, it is well established
that one can gain additional statistical power by examining the
distribution of p-values across a series of tests rather than
considering each of them individually [17]. Thus, we verified
whether the remaining 36 SNPs were showing an excess of low p-
values when compared to a typical distribution of p-values expected
for 36 true null hypotheses. The sum of log(1/pi) values obtained
with the 36 SNPs was only reached for 7 out of 10,000 simulations,
thus equating to a p-value of 0.0007, strongly suggesting the
occurrence of true alternative hypotheses amongst the 36 remaining
SNPs. The same approach was successively applied to the 35, 34,
33, 32, … SNPs with highest p-values, i.e. progressively dropping
the SNP with lowest p-values and verifying whether the remaining
distributions were still significantly skewed towards low values. The
outcome of this analysis is shown in Fig. 1. It indicates that the top
four SNPs, at least, are very likely to affect the risk of developing AS.
Discussion
We herein first confirm two previously established associations
with the risk to develop AS, respectively with the MHC and IL23R
loci.
In addition, we report a novel association between AS and a
SNP mapping at position 35,294,289 of human chromosome 17.
Remarkably, rs2872507 maps to a locus shown first to be
associated with asthma [6] and subsequently with CD [7].
Rs2872507 was shown to be associated with expression levels of
the closely linked ORMDL3 and GSDML genes in lymphoblastoid
cell lines, which therefore stood out as prime candidate genes
[6,7]. However we could not detect differential expression of
ORMDL3 in whole gut biopsies of patients with CD or AS.
Although this polymorphism has been shown to influence the
expression of ORMDL3 in lymphoblastoid cells, it is likely that such
influences might play only a marginal role in complex tissue such
as gut biopsies. Alternatively, SNPs in LD with rs2872507 might
have more profound control on the expression of ORMDL3.
Using a survey of SNPs surrounding the ORMDL3 gene
genotyped in the Welcome Trust case consortium dataset, no
association was found with AS (personal communication). The
population used in this study might contain a bias towards patients
with subclinical gut alterations, since the patients were sampled as
the result of a collaboration between the departments of
rheumatology and gastroenterology. HLA-B27, a well-known risk
factor associated with AS, has the tendency to misfold during class
I complex formation in the endoplasmic reticulum (ER). As such,
ORMDL3 represents an interesting candidate gene for AS, as this
protein resides in the ER and overexpression of this gene facilitates
the activation of the unfolded protein response [18].
By applying a method that seeks to extract information from the
distribution of p-values rather than individual ones, we provide
Table 1. Clinical features of the patient population recruited for intestinal ORMDL3 gene expression analysis.
Colonic biopsies Ileal biopsies
control CD UC AS control CD UC AS
N 21 39 10 14 17 24 11 10
Gender (M/F) 9/12 18/21 7/3 8/6 8/9 12/12 4/7 4/6
Age, yrs (mean, range) 50 (22–69) 38 (11–73) 45 (25–61) 36 (16–51) 51 (27–69) 37 (11–66) 32 (7–51) 35 (16–44)
Age at diagnosis (A1/A2/A3) 3/28/8 0/4/6 3/15/6 1/8/2
Disease location (L1/L2/L3/L4) 15/5/18/1 4/8/11/1
Rs2872507 (AA/AG/GG/unknown) 3/6/6/6 9/11/1/18 0/3/0/7 0/7/4/3 2/3/5/7 3/9/1/11 0/1/0/10 0/5/3/2
Medication intake:
no 21 30 7 2 17 19 10 1
5-aminosalicylates 0 9 3 0 5 1
NSAID 12 9
A1:0–16 yrs; A2:16–40 yrs; A3: $40 yrs; disease location is defined as maximal extension of inflammation before first resection. L1: ileal involvement only, L2: colonic
involvement only, L3: ileal and colonic involvement. NSAID: non-steroidal anti-inflammatory drugs.
doi:10.1371/journal.pone.0013795.t001
Risk Variants for CD and AS
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evidence for an addition of four novel AS risk loci. The three first
of these define an LD-based confidence interval encompassing one
gene each: NKX2-3, PTPN2 and ICOSLG [7]. As mentioned before,
PTPN2 is particularly interesting as it has been implicated before in
the pathogenesis of CD [7] and type I diabetes [19]. The sign of the
association is apparently the same for the three diseases, i.e. the
same allele increases risk for the three pathologies. ICOSLG is also
very interesting because of its known involvement in the regulation
of immune response [20,21]. The fourth SNP defines a confidence
interval encompassing 35 genes, includingMST1 which has recently
been implicated in the pathogenesis of CD [22].
One could argue that the observed skewed distribution of p-
values reflects population stratification rather than genuine
associations. While we cannot formally refute this possibility on
the basis of the available data, we consider this to be an unlikely
hypothesis. Indeed, the controls originated from the same
geographical region as the cases, namely Belgium, and were
subjected to the same ethnicity criteria. Moreover, the exact same
control cohort has been successfully used as confirmation cohort in
an association study for CD based on Belgian cases [7].
In conclusion, we herein provide evidence for an important
overlap between the determinants of inherited predisposition to
CD and AS. Prior to this study the MHC and IL23R loci were
known to be implicated in the susceptibility to both diseases. We
have studied an additional 37 recently defined CD risk loci. Given
the limited size of the studied AS cohort, the significance threshold
associated with a Type-I error of 5% (accounting for the
realization of 37 independent tests), was only exceeded for one
(ORMLD3) of the 37 SNPs not previously known to affect AS.
However, the distribution of p-values for the remaining 36 SNPs
was significantly skewed towards low p-values unless the top 5
SNPs were removed from the analysis, hence supporting at least
five novel associations with AS.
Materials and Methods
Ethics Statement
This study was approved by the ethics committee of the University
Hospital Ghent (nos. 2000/242 and 2004/242) and each participant
obtained a written informed consent form. This form was signed by
the participants and approved by the ethics committee.
Patients
All included patients fulfilled the modified New York criteria for
definite AS [23], were of self-reported white ancestry, born
between 1930 and 1986. Patients were followed at the Rheuma-
tology Department of the University Hospital in Ghent. The male
to female ratio was 2.4. Patients with abdominal inflammatory
symptoms were not included in this analysis.
Genotyping
Genotyping was performed using the Illumina Golden Gate
assay previously used on the Belgian-French cohort in the CD
meta-analysis [7]. The genotyping success rate for the AS patients
that were retained for analysis was $97% and all markers were in
Hardy-Weinberg equilibrium in the control population [7].
Figure 1. Association of 36 SNPs known to influence CD risk with AS. SNPs are ordered on the X-axis by increasing p-value. Y-axis: log10(1/p),
corresponding to (i) nominal p-values (gray), (ii) Bonferroni corrected p-values (blue), (iii) expected distribution of p-values assuming that all SNPs are
true null hypotheses (black), and (iv) the p-value of the distribution of individual p-values for the corresponding marker plus all the less significant
ones (red). The horizontal line corresponds to a p-value of 0.05. The names of gene of interest in the vicinity of the associated SNPs as well as the
number of genes in the confidence interval (defined according to [7]) are given for the five most interesting SNPs, exceeding the 0.05 significance
threshold using the approach that extracts information from the p-value distribution.
doi:10.1371/journal.pone.0013795.g001
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Quantitative real-time PCR
For ORMDL3 gene expression analysis, endoscopically healthy
biopsies were retrieved during colonoscopy. Total RNA was
extracted from the biopsies using the RNeasy Mini Kit (Qiagen
Benelux, Venlo, The Netherlands). The quality of each sample
was determined using automated gelelectrophoresis (Experion
Systems, Maynard, MA, USA, RQI range 7.6–10). Twenty ng of
total RNA was converted to cDNA and amplified using the WT-
Ovation RNA amplification system (Nugen Technologies, Bem-
mel, The Netherlands). Ten ng of amplified cDNA was used in
SYBRGreen real-time quantitative PCR using automated pipett-
ing (Caliper ALH3000, Caliper Life Sciences, Teralfene, Belgium).
Cycling conditions were 95uC for 10 minutes and 44 cycles of
95uC for 10 seconds and 60uC for 30 seconds (Bio-Rad CFX384,
Bio-Rad Laboratories, Nazareth, Belgium). Melting curve analysis
confirmed primers specificities. The amplification efficiencies of
the primer pairs were calculated using a standard curve of
reference genomic DNA. Amplification efficiency was determined
using the formula 1021/slope. ORMDL3 expression was normalized
with the geometric mean value of three reference genes. Primer
sequences for ORMDL3 detection were GTAAAAGGCATGTG-
CTGCAA; CCCAACCCCACTACAAGCTA (E= 105% R2=
0.999), for GAPDH TGCACCACCAACTGCTTAGC; GGC-
ATGGACTGTGGTCATGAG (E= 110%; R2= 0.990), for
HPRT TGACACTGGCAAAACAATGCA; GGTCCTTTTCA-
CCAGCAAGCT (E= 111%; R2= 0.998) and for SDHA TGG-
GAACAAGAGGGCATCTG; CCACCACTGCATCAAATTC-
ATG (E= 105; R2= 0.994).
Statistics
Marker allele frequencies were compared between AS cases and
previously described Belgian replication controls, using a one-sided
Fisher’s exact test imposing an allelic effect with the same sign as
observed for CD [7]. For the 36 SNPs that did not exceed
Bonferroni-adjusted significance thresholds, we compared the
distribution of p-values with that expected for 36 true null
hypotheses. This was achieved by comparing
P35
i~1 log 1=pið Þ
obtained with the real data, with the distribution of 10,000P35
i~1 log 1=rið Þ, where ri are random numbers drawn between 0
and 1. Gene expression differences between groups were evaluated
by the Kruskal-Wallis statistic with Dunn’s multiple comparison test.
Supporting Information
Table S1
Found at: doi:10.1371/journal.pone.0013795.s001 (0.22 MB
DOC)
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